8-K: Coya Therapeutics Prices Upsized $23M Public Offering

Coya Therapeutics, a clinical-stage biotechnology company, announced the pricing of an upsized public offering of common stock, expecting to raise approximately $23.0 million in gross proceeds.

Summary

• Coya Therapeutics, Inc. priced an underwritten public offering of 3,636,364 shares of its common stock at $5.50 per share.
• The underwriter, Lucid Capital Markets, LLC, was granted a 30-day option to purchase up to an additional 545,454 shares of common stock.
• Including the full exercise of the underwriter's option, the gross proceeds from the offering are expected to be approximately $23.0 million, before deducting underwriting discounts and commissions and estimated offering expenses.
• The offering is expected to close on or about October 27, 2025, subject to customary closing conditions.
• Net proceeds from the offering will be used for working capital and general corporate purposes, including funding the company's clinical development plan.
• Allele Capital Partners, LLC, through its executing broker-dealer, Wilmington Capital Securities, LLC, acted as financial advisor and will receive $200,000 in cash and warrants exercisable for 100,000 shares of common stock with an exercise price of $5.50 per share.

Sentiment

Score: 7

Explanation: The successful pricing of an upsized public offering, securing $23.0 million in gross proceeds, is a positive development for a clinical-stage biotech company. This capital infusion will support ongoing clinical development, which is crucial for its pipeline. However, the dilution for existing shareholders and the inherent risks of clinical-stage drug development temper the overall sentiment.

Positives

• The company successfully priced an upsized public offering, indicating market demand and confidence.
• Expected gross proceeds of approximately $23.0 million (including the full exercise of the underwriter's option) will significantly bolster working capital and fund critical clinical development.
• The inclusion of an underwriter's option for additional shares provides flexibility for further capital if demand remains strong.

Negatives

• The issuance of new shares will result in dilution for existing shareholders.
• Warrants issued to the financial advisor at the public offering price of $5.50 per share could lead to further dilution upon exercise.

Risks

• The proposed public offering is subject to market and other conditions, and there is no assurance as to whether or when it may be completed, or its actual size or terms.
• Forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially, as disclosed in the company's SEC filings.
• The company's ability to complete the public offering on the anticipated terms, or at all, is not assured.
• As a clinical-stage biotechnology company, Coya Therapeutics faces inherent risks associated with drug development, regulatory approvals, and commercialization of its product candidates.

Future Outlook

The company intends to use the net proceeds from the public offering for working capital and general corporate purposes, including funding its clinical development plan. The offering is subject to market and other conditions, and there is no assurance as to whether or when it may be completed, or its actual size or terms.

Management Comments

• Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, intends to offer and sell shares of its common stock in an underwritten public offering.
• The company intends to use the net proceeds from the proposed public offering for working capital and other general corporate purposes, including funding its clinical development plan.

Industry Context

Coya Therapeutics operates in the clinical-stage biotechnology sector, specifically focusing on neurodegenerative disorders by developing treatments that enhance regulatory T cell (Treg) function. This capital raise provides funding for its ongoing clinical development plan, including the ALSTARS Trial for COYA 302 in ALS, which is typical for biotech companies at this stage requiring significant capital for R&D and clinical trials.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Existing shareholders will experience dilution due to the issuance of new shares. The capital raise provides funding for future operations and clinical development, potentially increasing long-term value if successful.
• Employees: Continued funding supports the company's operations and clinical programs, providing stability and continuity for employees.
• Customers (future patients): The capital will fund clinical development, potentially accelerating the availability of new treatments for neurodegenerative disorders.
• Creditors: Improved financial liquidity from the capital raise may reduce credit risk.

Next Steps

• Closing of the public offering on or about October 27, 2025.
• Continued funding of the clinical development plan, including the ALSTARS Trial (Phase 2 for COYA 302 in ALS).
• The underwriter may exercise its 30-day option to purchase additional shares.
• Directors and executive officers are subject to a lock-up period until January 22, 2026.
• The company is prohibited from effecting certain variable rate transactions for 90 days after the Initial Closing Date.
• The underwriter has a right of first refusal for future capital raising transactions for six months.

Key Dates

Recommendation

While the successful capital raise is a positive for Coya Therapeutics, providing essential funding for its clinical development, the inherent risks of a clinical-stage biotechnology company remain significant. The dilution from the offering is a short-term negative. The funds are crucial for advancing its pipeline, but the outcome of clinical trials is uncertain. Therefore, a 'hold' recommendation is appropriate, awaiting further clinical data and progress.

Keywords

Coya Therapeutics, COYA, Public Offering, Common Stock, Underwritten Offering, Capital Raise, Biotechnology, Neurodegenerative Disorders, Treg, ALS, Clinical Development, Lucid Capital Markets, Allele Capital Partners, Warrants, Dilution